Human study PLS-00084

Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.

Other design · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects.primary · Clinical endocrinology · 2019-05-15 · PMID 31066084 · DOI

Design and participants

Design: Other design
Population: Women with polycystic ovary syndrome and healthy control subjects
Conditions: Polycystic ovary syndrome, Insulin resistance
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported
Funding: Research Support, Non-U.S. Gov't (publication type); funder not named in the record

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): The authors report that raised lipids increased circulating MOTS-c while insulin attenuated this response in humans. Eight weeks of moderate exercise did not change circulating MOTS-c in healthy controls or women with PCOS.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate endpoint: MOTS-c was only measured as an endogenous plasma biomarker. It was never administered, so no effect of giving MOTS-c can be inferred.
abstract only: Only the abstract is available; sample sizes, methods details and the full results are not reported in the record.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves metabolic health: not eligible (not primary study) for “Insulin sensitivity, glucose control or body weight”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 31066084, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 31066084, abstract (Methods, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
limitations: PMID 31066084, abstract (Methods, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 31066084, abstract (Objective, sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).